EC313 / Evestra - LARVOL DELTA

Next step in the development of mesoprogestins: the preclinical profile of EC313. (PubMed, Front Endocrinol (Lausanne)) - "This model shows the same features for the termination of pregnancy by antiprogestins such as Mifepristone and Ulipristal acetate (UPA) in humans. For an explanation of these findings, the possibility is discussed that the mixed agonistic/antagonistic feature of EC313 is tissue target-specific based on its super-additive synergism characteristic for active bifunctional agents. In conclusion, the specific pharmacodynamic profile of this compound opens the possibility for the development of a drug with a distinct pharmaco-endocrinological profile against uterine fibroids, endometriosis, and other PR-dependent gynecological diseases."

Journal • Preclinical • Endometriosis • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health • AR • ER

Contemporary approaches in the management of uterine leiomyomas. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "Many drugs show efficacy in patients with symptomatic uterine fibroids. UPA is one of the most studied and prescribed medicines for uterine fibroids; however, its usage has been restricted due to a few recent incidences of hepatic toxicity. Herbal drugs and natural supplements have also shown promising effects on uterine fibroids. The synergistic effects of nutritional and herbal supplements have been reported in certain cases, and should be studied in detail. Further research is warranted to identify the mode of action of the drugs, and to determine the precise conditions that would explain the causes of toxicity in some patients."

Journal • Review • Gynecology • Hepatology • Oncology • Solid Tumor • Uterine Leiomyoma • Women's Health

EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model. (PubMed, Sci Rep) - "Ulipristal acetate (UPA) a selective progesterone receptor (PR) modulator (SPRM) reduce the size of UFs, inhibit ovulation and lead to amenorrhea. The partial PR agonism and no signs of unopposed estrogenicity makes EC313 a candidate for the long-term treatment for UFs. Docking studies have provided a structure based explanation for the SPRM activity of EC313."

Journal • Preclinical • Gynecology • Hepatology • Infertility • Musculoskeletal Pain • Pain • Sexual Disorders • Solid Tumor • Uterine Leiomyoma